Advertisement


Rana R. McKay, MD, on RCC: Continuing Benefit After Halting Treatment

2017 Genitourinary Cancers Symposium

Advertisement

Rana R. McKay, MD, of the University of California, San Diego, discusses study findings on PD-1/PD-L1 responders with metastatic renal cell carcinoma who discontinue therapy for immune-related adverse events. (Abstract 467)



Related Videos

Prostate Cancer

Charles G. Drake, MD, PhD, on Prostate Cancer and Immunology: Expert Perspective

Charles G. Drake, MD, PhD, of Columbia University Medical Center, summarizes his keynote lecture on immunotherapy as a new frontier in prostate cancer and its synergistic use with traditional treatments.

Bladder Cancer

Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response

Roland Seiler, MD, of the University of British Columbia, discusses a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplatin-based neoadjuvant chemotherapy, and which patients show the most benefit. (Abstract 281)

Prostate Cancer

Guru Sonpavde, MD, on Prostate Cancer: Targeting DNA Alterations

Guru Sonpavde, MD, of the UAB Comprehensive Cancer Center, discusses his study on circulating tumor DNA alterations in metastatic castration-resistant prostate cancer and the therapeutic direction the data suggest. (Abstract 149)

Solid Tumors

George J. Bosl, MD, and Karim Fizazi, MD, PhD, on Germ Cell Tumors and Treatment Intensification: Pros and Cons

George J. Bosl, MD, of Memorial Sloan Kettering Cancer Center, and Karim Fizazi, MD, PhD, of Gustave Roussy and the University of Paris Sud, offer the “pro” and “con” viewpoints for treatment intensification in patients with poor-prognosis germ cell tumors with unfavorable marker decline.

Prostate Cancer

Joshua M. Lang, MD, on Prostate Cancer: Best of the Journals

Joshua M. Lang, MD, of the University of Wisconsin Carbone Cancer Center, discusses genomic alterations in DNA damage–repair pathways––more common in patients with prostate cancer than previously recognized–– and clinical trials with PARP inhibitors.

Advertisement

Advertisement




Advertisement